GlassScriptPhysician profile
Ivette C Bonet Velez
NPI 1316915887
$2,320.12
in general payments reported to CMS, 2019-2025
21 companies · $562 in 2025
The $562 reported for 2025 was more than what 85% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.77 · 2020: $166 · 2021: $296 · 2022: $386 · 2023: $368 · 2024: $503 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $463.50 | 2020-2025 | Xarelto, Erleada, Invega Sustenna |
| Merck Sharp & Dohme LLC | $377.08 | 2019-2025 | Capvaxive, Gardasil 9, Keytruda |
| Abbvie INC. | $212.16 | 2020-2025 | Rinvoq, Vraylar |
| Glaxosmithkline, LLC. | $207.53 | 2020-2024 | Trelegy Ellipta, Arexvy, Jemperli |
| Astrazeneca Pharmaceuticals LP | $171.82 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.65 | 2022-2025 | Jardiance |
| Eli Lilly Export S.A. Puerto Rico Branch | $127.92 | 2020-2022 | |
| Pbg Puerto Rico LLC | $127.59 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.24 | 2019-2022 | |
| Organon LLC | $54.47 | 2025 | Hadlima |
| Amgen INC. | $51.61 | 2021 | |
| Tolmar, INC. | $49.63 | 2024-2025 | Jatenzo, Eligard |
| Genentech, INC. | $39.38 | 2023-2025 | Itovebi, Lunsumio |
| Madrigal Pharmaceuticals | $35.71 | 2025 | Rezdiffra |
| Viiv Healthcare Company | $34.93 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $32.27 | 2025 | |
| Ucb, INC. | $27.78 | 2025 | Rystiggo |
| Vifor Pharma, INC. | $27.38 | 2025 | Veltassa |
| Mirati Therapeutics, INC. | $25.00 | 2023 | Krazati |
| Teva Pharmaceuticals USA, INC. | $24.15 | 2024 | |
| Novo Nordisk INC | $22.32 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivette Bonet Velez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.